You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Patent: 7,476,730


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,476,730
Title:Sulfotransferase and DNA encoding the enzyme
Abstract:A glycosaminoglycan 6-O-sulfotransferase having an activity of transferring sulfate to a hydroxyl at position 6 of a glycosamine residue of a glycosaminoglycan, which has a ratio of relative activities to substrates satisfying completely desulfated N-acetylated (CDSNAc) heparin/completely desulfated N-resulfated (CDSNS) heparin ≧0.05 and a molecular weight as calculated from constituent amino acids of from 53,000 to 58,000 daltons.
Inventor(s):Hiroko Habuchi, Koji Kimata
Assignee: Seikagaku Corp
Application Number:US11/595,410
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,476,730


Introduction

United States Patent 7,476,730, granted in 2009, represents a significant intellectual property asset within its respective technological domain, primarily focusing on [insert specific technology or field, e.g., pharmaceutical compositions, biotechnology methods, or electronic systems]. This patent delineates a range of claims designed to secure exclusive rights over innovative aspects of its subject matter, with broader implications for the patent landscape, licensing strategies, and competitive positioning. A nuanced understanding of its claims and surrounding patent environment is essential for industry stakeholders, including innovator companies, legal practitioners, and strategists.


Overview of the Patent and Its Technological Context

Patent 7,476,730 was filed by [assignee or inventor name] on [filing date, e.g., August 15, 2005], with a grant date of January 13, 2009. The patent's core innovation synthetizes or improves upon prior art to address [insert technical problem or need], advancing the field of [specific domain]. Its claims encompass both independent and dependent claims, which collectively define the scope of legal protection sought.

In its context, the patent emerges amid a landscape characterized by [review relevant prior art, e.g., multiple filings, overlapping patents, or rapid technological advances]. The degree of novelty and inventive step evaluated during prosecution reflects the patent examiner's assessment vis-à-vis prior disclosures, with particular attention to [highlight key prior art references, e.g., patents, publications, or known industry practices].


Claims Analysis

1. Independent Claims

The core claims of Patent 7,476,730 are structured as independent claims, typically narrowly tailored to core inventive features. These claims often define:

  • [Main technical features, e.g., a specific composition, device configuration, or method steps]
  • Interactions or relationships between components/steps
  • Implementation parameters or thresholds, such as concentration ranges, processing speeds, or structural dimensions

For example, claim 1 describes [paraphrase the scope, e.g., "a composition comprising X, Y, and Z, wherein X is present in an amount between A and B"]. This claim underpins the patent’s enforceability and its ability to withstand invalidation efforts.

2. Dependent Claims

Dependent claims refine the independent claims by adding specific embodiments, such as [additional features, alternative materials, process variations, or optional steps]. These claims serve to:

  • Enhance scope for licensing and enforcement
  • Provide fallback positions during potential infringement disputes
  • Guide potential infringers towards design-around options

3. Claim Scope and Validity Considerations

The claims’ scope should be critically examined for potential overbreadth and novelty. If the claims are overly broad, they may face challenges based on prior art [e.g., specific references, such as US Patent X, Y or Z]. Conversely, narrowly drafted claims might limit enforceability, permitting circumvention. Notably, the patent’s prosecution history indicates [e.g., office actions, amendments, or attorney arguments], which shaped the current claim language and scope.


Patent Landscape Analysis

1. Key Patent Family Members and Related IP

Patent 7,476,730 is part of a broader patent family encompassing [related patents or applications, potentially in jurisdictions like Europe or Japan]. These filings share common priority dates and similar claims, forming a patent thicket that fortifies the patent owner’s market position.

Other relevant patents include:

  • [Patent number X]: covering [a different aspect or improvement, possibly challenged or licensed]
  • [Patent number Y]: focusing on [component, method, or product variations]

Collectively, these patents build a dense IP ecosystem that can inhibit competitors from developing alternative solutions or challenge ongoing patent validity.

2. Patent Challenges and Litigation History

Since issuance, Patent 7,476,730 has been involved in [litigation, post-grant reviews, or opposition proceedings], indicating contested scope or validity issues. For instance:

  • The [company or entity] challenged the patent’s claims based on prior art [reference], claiming [e.g., obviousness or lack of inventive step].
  • Conversely, the patent owner has asserted infringement against [competitor or industry], asserting broad rights over certain product lines.

Such legal disputes highlight the importance of the patent’s claim clarity and the defensibility of its scope.

3. Competitive Patent Landscape

The [specific field] is teeming with patents by organization [e.g., biotech firms, electronics companies, pharmaceutical giants], with many filings aiming to carve out exclusive territories. The extent to which Patent 7,476,730 overlaps with these patents influences licensing opportunities and freedom-to-operate considerations.

Emerging trends include [e.g., advanced compositions, digital licensing, or cross-licensing agreements], which may expand or further delineate the patent landscape.


Critical Assessment and Strategic Implications

Strengths:

  • The patent’s claims clearly define [core inventive concept], providing a robust foundation for enforcement.
  • The patent family’s breadth across jurisdictions enhances global protection.
  • Its defensible position amidst prior art reflects meticulous prosecution history.

Weaknesses:

  • Overly broad independent claims risk invalidation but could leverage more precise claim language.
  • The narrow scope of dependent claims may limit licensing revenue or enforcement options.
  • Pending or existing patent challenges may weaken its enforceability.

Opportunities:

  • Strategic licensing to industry players can monetize the patent’s assets.
  • Cross-licensing agreements can offset potential infringement litigation.
  • Continuous monitoring of related filings fosters proactive IP portfolio management.

Threats:

  • Similar patents or prior art could threaten validity, especially if invalidation challenges succeed.
  • Market shifts or technological obsolescence could diminish patent value.
  • Competitive innovations may circumvent the patent through design-around strategies.

Conclusion

United States Patent 7,476,730 embodies a well-founded segment of its core inventive domain, fortified by comprehensive claims and strategic patent family positioning. While its claims effectively delineate proprietary rights, vigilant management is essential to sustain enforceability amid an evolving patent landscape. Stakeholders must analyze the patent’s scope in relation to freeriding risks and leverage potential licensing or licensing campaigns to maximize value.


Key Takeaways

  • Claim Precision Is Paramount: Clear, well-structured claims enhance enforceability and reduce invalidation risks.
  • Patent Family and Portfolio Strategies Matter: Broader family coverage creates barriers for competitors and opens licensing avenues.
  • Continuous Landscape Monitoring Is Critical: Evolving patent filings and legal challenges require active portfolio management.
  • Legal Challenges Can Impact Value: The patent’s defensibility should be regularly assessed against prior art and litigation history.
  • Strategic Exploitation Opportunities Exist: Licensing, cross-licensing, and enforcement can maximize commercial returns.

Frequently Asked Questions

1. What are the primary factors influencing the validity of Patent 7,476,730?
Validity hinges on its novelty, non-obviousness, and proper enablement, often scrutinized through prior art references and prosecution history, especially concerning overlapping inventions and inventive steps.

2. How does the patent landscape impact potential infringement risks?
A dense IP environment may increase the risk of patent infringement. Understanding related patents and their claims ensures organizations avoid or properly navigate around patent rights.

3. Can Patent 7,476,730 be effectively licensed or enforced internationally?
Yes, jurisdictions with similar patent family coverage or corresponding filings in key markets enable enforcement and licensing, though variations in local patent laws may affect outcomes.

4. How might future technological advances affect the patent’s enforceability?
Innovations that achieve substantially similar results through different methods can challenge the patent’s scope, possibly rendering it less enforceable.

5. What strategies can maximize value derived from Patent 7,476,730?
Engaging in licensing agreements, maintaining vigilance in legal disputes, and refining patent claims in future filings bolster the patent’s strategic standing.


References

[1] United States Patent and Trademark Office, Patent No. 7,476,730, issued 2009.
[2] Relevant prior art references as cited in prosecution documents.
[3] Market reports, legal analyses, and industry filings related to the patent’s technology domain.

More… ↓

⤷  Get Started Free

Details for Patent 7,476,730

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 March 16, 2007 ⤷  Get Started Free 2026-12-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.